
NAD+
Nicotinamide Adenine Dinucleotide
Also called nicotinamide adenine dinucleotide, NAD, NMN, nicotinamide mononucleotide, NR, nicotinamide riboside
The coenzyme that powers cellular energy and repair
NAD+ is a molecule every cell uses to turn food into energy, and levels fall with age. It is offered as an IV drip, an injection, and as oral precursors called NMN and NR. Almost all the human trial evidence is for the oral precursors, not for the drips and injections clinics offer.
A molecule every cell spends constantly to turn food into energy, and that your DNA repair enzymes spend too. Levels fall with age, which is the reason it is marketed. The catch is delivery: NAD+ itself does not cross into cells easily, so almost every trial tested smaller oral building blocks (NMN and NR) rather than the drips clinics offer.
- Route studied
- Oral NMN or NR (trials); intravenous (clinic use)
- Status
- Precursors sold as supplements; IV and injected NAD+ are not approved drugs
Human trials published, with more underway
2,609 papers · 64 clinical trials
What NAD+ has been studied for
The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.
- Energy and fatigue
- The most common reason people look it up, and the one with the least trial evidence behind it.
- Metabolic health
- The best single human result: improved muscle insulin sensitivity in prediabetic women.
- Ageing and cell health
- The whole rationale, since NAD+ falls with age and is required by repair enzymes.
- Cognition
- Tested in older adults with mild cognitive impairment, which is a real trial rather than a marketing claim.
Mechanism of Action
How NAD+ works
Nearly every reaction that turns food into usable energy inside your cells passes electrons around, and NAD+ is what carries them. It is less a nutrient than a currency: cells spend it constantly, all day, to keep the lights on.
Two other jobs draw on the same pot. The repair enzymes that fix damaged DNA spend NAD+ to work. So do the sirtuins, a family of enzymes tied to how cells handle stress and ageing. When NAD+ runs low, those jobs compete with basic energy production for what is left.
Levels fall with age. That single fact is the reason this category exists.
Why the research uses precursors
NAD+ is a large, electrically charged molecule, and cells do not simply let it walk in. So the research went after its raw materials instead: NMN and NR, smaller molecules the body assembles into NAD+ once they are inside.
That is why nearly every trial tested an oral capsule rather than the drip offered in clinics: getting the finished molecule into a cell is the hard part, and a precursor sidesteps it.
What has actually been shown
The strongest result, published in Science, is narrow and worth reading precisely. Oral NMN improved how well muscle responded to insulin in prediabetic women. It did not change their weight, blood pressure or liver fat.
That is a specific finding, not a general rejuvenation, and the gap between the two is where most of the marketing lives.
NAD+ side effects: what studies reported
Intravenous NAD+ has one distinctive reported effect: infused quickly, it causes chest tightness, cramping and nausea for a few minutes, which settle when the infusion slows. The oral precursor trials reported few side effects.
Reported with intravenous use
- Chest tightness or pressure during a fast infusion
- Stomach cramping and nausea
- Flushing and feeling hot
- Headache
- A wired feeling afterwards
Worth keeping an eye on
- Injection-site reactions with the subcutaneous form
- Intravenous and injected NAD+ have far thinner human evidence than the oral precursors
Dose-related findings. With intravenous NAD+, the reported effects relate to infusion speed more than to the total amount.
Source: Reports from clinic infusion practice, plus the oral precursor trials. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about NAD+ belong with a licensed clinician who knows your history.
Your Genetics & NAD+
The genes involved in how NAD+ works
NAD+ works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.
NAMPT is the rate-limiting enzyme that recycles NAD+. Variants have been studied for their association with metabolic traits. No study has tested whether they change response to NAD+ or its precursors.
SIRT1 builds a sirtuin enzyme that uses NAD+. Variants have been studied for their association with metabolic traits; any link to NAD+ supplementation is untested.
FOXO3 · ••
FOXO3 variants such as this one are associated with longevity in several human population studies. FOXO3 acts downstream of sirtuin signalling; any link to NAD+ supplementation is untested.
SOD2 · ••
The Ala16Val variant has been associated with differences in how the SOD2 antioxidant enzyme reaches mitochondria. Pathway context only.
The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.
Which of these variants do you carry?
Your report reads the DNA file you already have against this research.
Often discussed alongside
Compounds that come up next to NAD+ in research and discussion. Each has its own page. None of this is a suggestion to combine them.

MOTS-c
also studied for mitochondrial functionEmerging EvidenceMitochondrial Open Reading Frame of the 12S rRNA Type-c
A peptide written not in the cell's main genome but in the tiny separate one mitochondria carry, a leftover from when they were free-living bacteria. In preclinical work it behaves like an exercise signal, switching on the same fuel-burning pathway a hard workout does. Levels fall with age, which is why it turns up in longevity conversations, and essentially all of the outcome data are preclinical.
3
Gene variants
25+
Studies

SS-31
also studied for mitochondrial functionModerate EvidenceSS-31 (Elamipretide / Bendavia / MTP-131)
A peptide that goes to one specific place: the inner membrane of the mitochondria, where it binds a fat called cardiolipin. It is the rare compound here that is a genuine pharmaceutical, tested in real trials, and its honest record includes a large trial that failed. Also known as elamipretide.
4
Gene variants
50+
Studies
Access
Access and legal status
NAD+: Precursors sold as supplements; IV and injected NAD+ are not approved drugs. Decisions about any prescription medicine belong to a prescriber. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.
Your DNA and NAD+: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →
Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.
Worth knowing about NAD+
Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.
- The drip is not what was studied
- The trials below used oral NMN or NR. IV NAD+ has far thinner human evidence, and fast infusions are widely reported to cause chest tightness, flushing and nausea.
- Raising NAD+ is not the same as getting younger
- Trials reliably show blood NAD+ rising. Whether that produces the energy, ageing and cognitive benefits it is marketed for is a separate question, and most of these studies were too short or too small to answer it.
- Sold as a supplement, so quality varies
- NMN and NR are sold as supplements rather than medicines in most places, which means no one is required to verify that the bottle contains what the label says.
The evidence behind NAD+
Read the route before the results. Nearly every randomised trial here gave an oral precursor, NMN or NR, which the body converts to NAD+. What clinics offer is usually an IV drip or an injection, and that is not what was tested. The distinction matters because NAD+ is a large, charged molecule that does not simply cross into cells intact, which is why the research went after precursors in the first place. Treating the oral trial results as evidence for a drip is the single most common mistake made about this compound.
The literature, counted
Counted in PubMed on 3 August 2026 for nicotinamide riboside OR nicotinamide mononucleotide OR NAD+ precursor. Every figure links to the search that produced it, so you can re-run it. “Tagged human” is not the same as a human trial: that tag also covers work on human cells and reviews discussing people, which is why the trial count is given separately.
Studied in people
3 of 3The only kind that directly answers whether it works in humans.Science · 2021
HumanNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M, Yoshino J, Kayser BD, et al.
The strongest human result in this area, and published in Science. Oral NMN improved muscle insulin sensitivity in prediabetic women. Note what it did not show: no change in body weight, blood pressure, liver fat or most other measures, so it is a specific finding rather than a general rejuvenation.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women: source for NAD+ (opens in a new tab)Randomised controlled trial
Read the paperGeroScience · 2023
HumanThe efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Yi L, Maier AB, Tao R, et al.
A multicentre trial in healthy middle-aged adults that tested several oral doses of NMN against placebo for both effect and safety.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial: source for NAD+ (opens in a new tab)Randomised controlled trial
Read the paperGeroScience · 2024
HumanA randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
Orr ME, Kotkowski E, Ramirez P, et al.
Tests the cognitive claim properly, in older adults who already have mild cognitive impairment, using oral nicotinamide riboside against placebo.
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment: source for NAD+ (opens in a new tab)Randomised controlled trial
Read the paper
Every source behind this page74 more
- NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NRYoshino J, Baur JA, Imai SI · Cell Metabolism · 2018Review
- Regulation of and challenges in targeting NAD(+) metabolismCovarrubias AJ, Perrone R, Grozio A, Verdin E · Nature Reviews Molecular Cell Biology · 2024Review
- Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future DirectionsFreeberg KA, Udoh CE, Craighead DH, et al. · Journals of Gerontology: Series A · 2023Review
- Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD(+) synthesis via enterohepatic circulationYang Y, Zhang N, Zhang G, et al. · Science Advances · 2025Preclinical
Everything we cite for NAD+, including preclinical work and early research. Each link goes to the source itself, so you can judge it rather than take our word for it.
Last updated · literature counts verified against PubMed on
Frequently Asked Questions
Why do NAD+ levels matter for aging?
NAD+ is used both for mitochondrial energy production and by the sirtuin and PARP enzymes that repair cells and DNA. Levels decline with age, which is thought to contribute to falling energy and slower repair. Whether raising NAD+ in people changes any of that is not yet shown.
What has been shown in human trials?
The clearest result: oral NMN improved muscle insulin sensitivity in prediabetic women, without changing weight, blood pressure or liver fat (Science, 2021). Trials reliably show blood NAD+ rising on oral NMN or NR. Intravenous NAD+ has far thinner evidence.
Do genes affect NAD+ response?
No study has tested whether any genotype changes response to NAD+ or its precursors. NAMPT, SIRT1, FOXO3 and SOD2 sit on the NAD+ recycling, sirtuin and mitochondrial pathways, and some of their variants have been associated with metabolic or longevity traits. A DNA report can show which versions you carry and what that research does and does not show.
Watch
What clinicians and researchers say about NAD+
30 minNAD+ in Aging: Role of Nicotinamide Riboside and Nicotinamide MononucleotideRhonda Patrick · ResearcherNAD+
7 minDoctor Reviews NAD+ vs Peptides - Which Does MORE?Ashley Froese · EducatorNAD+IpamorelinCJC-1295
2 hr 17 minDr. Craig Koniver - The Godfather of Peptides | SRS #330Shawn Ryan Show · PodcastBPC-157NAD+SS-31Your DNA and NAD+
What the research says about your variants.
The report
Which NAD+ variants do you carry?
Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.
Read my DNA, $99